Novo Nordisk Halts Wegovy Sales on Hims & Hers, Claiming “Deceptive Marketing” Practices

June 25, 2025

Novo Nordisk terminates its collaboration with Hims & Hers Health, Inc. due to concerns about deceptive marketing and allegations of selling illegitimate, knockoff versions of the pharmaceutical firm’s weight-loss drug, Wegovy.

“After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk,” a Novo Nordisk spokesperson told CBS MoneyWatch. “This is unacceptable, and that is why we have decided to end the collaboration.”

Read more at CBS News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement